Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donald Harper

Allergy & Immunology Mechanicsburg, PA Medical Doctor

NPI 1760440184 CMS profile 124557

1700 Bent Creek Blvd Ste 210, Mechanicsburg, PA 17050

Open in the dashboard

General payments

$142,434

1,463 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donald Harper of Mechanicsburg, PA is reported in the CMS Open Payments database as having received $142,434 across 1,463 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,612 238
2024 General $13,791 214
2023 General $24,544 228
2022 General $17,678 219
2021 General $30,741 209
2020 General $16,679 176
2019 General $22,389 179

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Harper
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Donald Harper were reported at $16,612. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Donald Harper Allergy & Immunology median Middle half National median
2019 $22,389 $594 $163–$1,512 $163
2020 $16,679 $426 $106–$1,233 $114
2021 $30,741 $638 $157–$1,708 $132
2022 $17,678 $790 $205–$1,961 $149
2023 $24,544 $852 $220–$2,147 $160
2024 $13,791 $865 $203–$2,267 $164
2025 $16,612 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $60,391 393 payments
  2. GlaxoSmithKline, LLC. $31,122 254 payments
  3. Regeneron Healthcare Solutions, Inc. $18,098 142 payments
  4. Genzyme Corporation $9,788 102 payments
  5. Amgen Inc. $6,329 40 payments
  6. Genentech USA, Inc. $5,985 43 payments
  7. Pfizer Inc. $1,571 88 payments
  8. Grifols USA, LLC $1,011 52 payments
  9. CSL Behring $944 45 payments
  10. Novartis Pharmaceuticals Corporation $720 29 payments
  11. Other $6,476 275 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $106,765 80 payments
  2. Food and Beverage $27,883 1,345 payments
  3. Consulting Fee $5,155 4 payments
  4. Travel and Lodging $2,216 26 payments
  5. Education $415 8 payments
Products named General payments · program years 2019–2025
  1. FASENRA Respiratory $23,469 134 payments
  2. TRELEGY ELLIPTA $19,129 147 payments
  3. DUPIXENT Inflammation And Immunology $17,684 123 payments
  4. TEZSPIRE Respiratory $17,418 85 payments
  5. FASENRA Respiratory $11,431 42 payments
  6. DUPIXENT Immunology $6,826 156 payments
  7. Xolair $6,158 43 payments
  8. DUPIXENT Immunology $4,274 20 payments
  9. TEZSPIRE Inflammation $2,993 35 payments
  10. BREZTRI $998 48 payments
  11. Other $15,795 759 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,634

Median for Allergy/ Immunology: 449

Drug cost

$834,037

Median for Allergy/ Immunology: $169,700

Branded share of claims

49.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 54 $205,424
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 48 $127,308
Dupixent Syringe Dupilumab Brand 30 $114,869
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 103 $98,435
Xolair Omalizumab Brand 24 $56,388
Nucala Mepolizumab Brand 11 $43,576
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 54 $40,877
Breo Ellipta Fluticasone/Vilanterol Brand 79 $40,864
Spiriva Respimat Tiotropium Bromide Brand 28 $17,794
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 90 $16,259

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$286,971

Of which drugs: $233,062

Medicare patients

230

Average age 72

Services billed

10,102

150 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 53%
Diabetes 24%
Osteoporosis 22%
Depression 21%
Chronic kidney disease 20%
Ischemic heart disease 17%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 19 5,671 $168,890

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
$5,199 — —
TEZSPIRE
$4,699 — —
DUPIXENT
$1,039 84 —
XOLAIR
$630 24 5,671
AIRSUPRA
$371 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,463 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record